Genelux Corp

Research Genelux Corp (GNLX) on Bullrun: market cap USD 130.04M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerGNLX
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 130.04M
• Financial periodFY2025
• RevenueUSD 8.00K
• Revenue growth0.0%
• Net income-USD 32.15M
• Free cash flow-USD 26.37M

Valuation Snapshot

latest market cap is USD 130.04M.

About Genelux Corp

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform;

Frequently asked questions

What is Genelux Corp's market cap?

Genelux Corp's market capitalization is USD 130.04M.

What does Genelux Corp do?

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.